Teva Drops Most in 6 Weeks After U.S. Ruling on Copaxone

Teva Pharmaceutical Industries Ltd. declined the most in six weeks in Tel Aviv trading after a U.S. court invalidated a 2015 patent for the top-selling Copaxone medicine.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.